The Metamorphosis of Biopharmaceutical Innovation #BIO-Europe2015

26/03/2015 - 6 minutes

Innovation can occur in many different ways, and biopharmaceutical innovation is no exception. The pipelines of big Pharmas have fewer candidates, R&D costs are skyrocketing, internal research programs tend to shrink and open innovation is raising. This metamorphosis is happening right now and the plenary session of Bio-Europe Spring 2015 focused on this subject. A great opportunity to give the view of these world leading speakers.


After Sanofi’s CEO Serge Weinberg presentation on how Sanofi shifted from Chemistry to Biotech, I looked up the names of the Plenary session’s speakers. Amongst them were Antoine Papiernik, managing director at major european Biotech VC-fund Sofinnova Partners, ranked #67 on Forbes’ top VC ranking, Pierre-Henri Benhamou, CEO of DBV, the first French Biotech company to enter NASDAQ, Maya Said, VP and Head of external R&D at Sanofi, Jakob Dupont, CMO of OncoMed Pharmaceuticals, and Joseph Truitt, CEO of NASDAQ-listed Achillion Pharmaceuticals.

Such a panel could only lead to an exciting discussion.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member